Archive - September 2018
ITF Pharma Announces FDA Approval of Tiglutik (riluzole) Oral Suspension for the Treatment of Amyotrophic Lateral Sclerosis (ALS)
The PharmaTimes Marketer of the Year competition closes for entry next Friday – don’t miss this great opportunity!
Pharmaceutical Manufacturing Announces Updated Editorial Advisory Board
FDA gives Loxo breakthrough tag for second cancer drug
Novartis sells off part of Sandoz portfolio
Sangamo’s first gene-editing trial doesn’t convince investors
FDA extends review time for Roche’s Tecentriq/Avastin combo
Teva drops development of laquinimod